Qulipta can start reducing migraines within the first day of treatment, with measurable improvements in weekly migraine frequency by the end of week one. The drug reaches steady levels in your bloodstream by day three of daily dosing, and clinical trials evaluated its full benefit over 12 weeks.
What Happens in the First Week
Qulipta works faster than many people expect from a preventive migraine medication. In a pooled analysis of three large clinical trials published in Neurology, patients taking Qulipta were more likely than those on placebo to avoid having a migraine on day one of treatment. By the end of the first week, average weekly migraine days were already lower in the treatment group compared to placebo.
This early effect lines up with how the drug behaves in your body. Qulipta has a half-life of about 11 hours, meaning it clears and replenishes quickly with each daily dose. After three consecutive days of dosing, blood levels stabilize at a consistent therapeutic range. That rapid buildup helps explain why some people notice a difference within days rather than weeks.
Beyond just fewer migraines, patients in these trials also reported improvements in daily functioning within the first one to two weeks. They had less difficulty performing physical activities and reported better overall quality of life scores early in treatment.
The 12-Week Picture
While early relief is possible, the clinical trials that led to Qulipta’s approval were all designed around a 12-week treatment period. This is the timeframe used to measure the drug’s full preventive benefit for both episodic migraine (fewer than 15 migraine days per month) and chronic migraine (15 or more days per month). Benefits continued to build over that window, with monthly migraine days dropping progressively during the first four weeks and stabilizing from there.
If you’ve just started Qulipta and aren’t sure whether it’s working, most neurologists will recommend staying on it for at least 12 weeks before making a judgment. A rough first week doesn’t necessarily predict long-term results, and some people experience a more gradual reduction in migraine frequency rather than an immediate one.
How Qulipta Prevents Migraines
Qulipta blocks receptors for a protein called CGRP, which plays a central role in triggering migraine pain. During a migraine, CGRP is released around the brain’s protective membranes, activating pain-sensing nerve fibers. Qulipta sits on those receptors and reduces how strongly those nerve fibers respond.
Research from Mount Sinai found that Qulipta partially dials down the activity of two types of pain fibers in the brain’s outer lining, each on a slightly different timeline. It dampens one type of fiber within the first hour and another type over the following two to three hours. This dual action on different nerve fiber types distinguishes it from injectable CGRP-blocking treatments, which tend to affect only one fiber type. Because Qulipta is a small molecule taken by mouth with a relatively short half-life, it needs to be taken every day to maintain its protective effect.
Dosing and Whether It Affects Speed
Qulipta comes in 10 mg, 30 mg, and 60 mg tablets, all taken once daily. For chronic migraine, the recommended dose is 60 mg once daily. For episodic migraine, lower doses are also approved. Clinical trials didn’t show that higher doses produce faster onset of action. The early improvements seen in the first week appeared across dosage groups. The main differences between doses showed up in overall migraine reduction and side effect rates over the full treatment course, not in how quickly the drug kicked in.
A Canadian clinical review noted that the 60 mg once-daily dose is generally preferred in practice because it’s simpler and provides the same level of benefit as split-dosing regimens, with better adherence.
Side Effects in the Early Weeks
The most common side effects are nausea, constipation, and fatigue. These tend to show up before the full migraine benefit does, which can be discouraging. In clinical trials, nausea affected 5% to 9% of patients depending on dose (compared to 3% on placebo), constipation affected 6% to 8% (versus 2% on placebo), and fatigue affected 4% to 5% (versus 4% on placebo).
These side effects were mild enough that very few people stopped treatment because of them. Only 0.6% of trial participants discontinued due to nausea, 0.5% due to constipation, and 0.2% due to fatigue. For most people, these issues either resolve on their own within the first few weeks or remain manageable alongside the migraine reduction.
What a Realistic Timeline Looks Like
Here’s a practical way to think about what to expect:
- Days 1 to 3: The drug reaches steady levels in your blood. Some people notice fewer migraines almost immediately, though this varies.
- Weeks 1 to 2: Measurable reductions in weekly migraine days and early improvements in daily functioning are typical at this stage.
- Weeks 4 to 12: Monthly migraine days continue to decrease. This is the window where the full scope of benefit becomes clear.
Qulipta is one of the faster-acting preventive migraine treatments available. Older preventive options like certain blood pressure medications or antidepressants used for migraine often take four to six weeks before any benefit appears. Qulipta’s ability to show results within the first week is a meaningful advantage for people who need relief sooner.